Journal of Clinical Research & Bioethics

Covid-19 Clinical Research and Ethical Dilemmas

The coronavirus disease 2019 (COVID-19) pandemic placed an extraordinary demand on health systems and healthcare providers all over the world. The pandemic presented a number of unprecedented challenging ethical issues. Across the globe, hospitals are being challenged by a large number of patients presenting to the emergency room for treatment, creating scarcities of critical care resources, and uncovering the need for formal crisis standards of care.

Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) is spreading in almost every country, causing widespread health challenges and social instability. Hence, there is a necessity to continue some ongoing research studies safely, a critical need for novel research into the prevention and treatment of COVID-19, and we must try to anticipate the ethical and social implications of this global pandemic.

Nicholas S is an Assistant Professor in University Hospitals, USA. He has vast experience in dealing with Concentration in Clinical Research & Bioethics. His international experience includes various programs, contributions and participation in different countries for diverse fields of study.

We encourage potential authors and researchers to take part in this special issue and help us in bringing novel medical and clinical approaches for dealing with coronavirus (Covid-19)”.

The Journal will be accepting novel research articles, review articles, perspective studies, clinical trial protocols, case reports and letter to editors on all topics which justifies with the scope of the special issue “Covid-19 Clinical Research and Ethical Dilemmas”

There will be two modes of manuscript submission. The authors can directly submit their manuscript through e-mail at manuscripts@walshmedicalmedia.com
or through our online submission system at: https://www.longdom.org/submissions/clinical-research-bioethics.html

The acceptance of article for the special issue closes on 20th of December 2020. We appreciate your participation.